HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc06-2267v1 30/6/1605    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koh, K. K. Articles by Shin, E. K. Search for Related Content PubMed PubMed Citation Articles by Koh, K. K. Articles by Shin, E. K. Social Bookmarking                What's this?

Efonidipine Simultaneously Improves Blood Pressure, Endothelial Function, and Metabolic Parameters in Nondiabetic Patients With Hypertension

¹ Department of Cardiology, Gil Heart Center, Gachon Medical School, Incheon, Korea
² Diabetes Unit, Laboratory of Clinical Investigation, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, Maryland
³ Department of Cardiology, Laboratory Medicine, Gachon Medical School, Incheon, Korea
⁴ Department of Statistics, Ewha Womans University, Seoul, Korea

Address correspondence and reprint requests to Kwang Kon Koh, MD, Professor of Medicine, Department of Cardiology, Gil Heart Center, Gachon Medical School, 1198 Kuwol-dong, Namdong-gu, Incheon, Korea 405-760. E-mail: kwangk@gilhospital.com

Abbreviations: CCB, calcium channel blocker • DBP, diastolic blood pressure • SBP, systolic blood pressure • QUICKI, quantitative insulin sensitivity check index

The first 20% of the full text of this article appears below.

	INTRODUCTION

 
Hypertension is characterized by endothelial dysfunction and frequently clusters with metabolic disorders that are characterized by insulin resistance (1,2). These comorbidities may be explained, in part, by reciprocal relationships between endothelial dysfunction and insulin resistance (1). By contrast with calcium channel blockers (CCBs), treatment of hypertension with ß-blockers and diuretics is associated with a higher risk of type 2 diabetes (3). This advantage of CCBs may relate to specific mechanisms that target the vicious synergy between endothelial dysfunction and insulin resistance. CCBs activate nitric oxide (NO) synthase in vitro and enhance NO production in vivo (4). This may impact on the roles of adiponectin, leptin, and resistin to influence metabolic signals, inflammation, and atherosclerosis (5–7).

Efonidipine hydrochloride is a 1,4-dihydropyridine–type CCB with long-lasting vasodilator actions and little reflex tachycardia (8). Efonidipine improves endothelial function in patients with hypertension when compared with doses of nifedipine that result in comparable decreases in mean blood pressure (9). Therefore, we hypothesized that efonidipine therapy may simultaneously improve endothelial dysfunction, adipocytokine profiles, and other metabolic parameters in nondiabetic patients with hypertension.

	RESEARCH DESIGN AND METHODS—

 
We evaluated effects of efonidipine in a randomized, double-blind, placebo-controlled, crossover study. Thirty-nine hypertensive patients (systolic blood pressure [SBP] <180 mmHg and diastolic blood pressure [DBP] <110 mmHg) were considered eligible for this study. We excluded patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency. None of our subjects were diabetic (based on history or criteria according to the Report of the Expert Committee on the Diagnosis and Classification . . . [Full Text of this Article]

	RESULTS—

 

	CONCLUSIONS—

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. K. Koh, S. M. Park, and M. J. Quon Leptin and Cardiovascular Disease: Response to Therapeutic Interventions Circulation, June 24, 2008; 117(25): 3238 - 3249. [Full Text] [PDF]

				K. K. Koh, M. J. Quon, S. H. Han, Y. Lee, J. Y. Ahn, S. J. Kim, Y. Koh, and E. K. Shin Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients Diabetes Care, April 1, 2008; 31(4): 776 - 782. [Abstract] [Full Text] [PDF]